GlassScriptPhysician profile
Dhillon Zaver
NPI 1871029025
$5,118.57
in general payments reported to CMS, 2019-2025
19 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $418 · 2022: $757 · 2023: $952 · 2024: $1,313 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,943.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,131.09 | 2021-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $677.73 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $545.36 | 2022-2025 | Tecnis Simplicity, Tecnis Iol, Veritas Vision System |
| Abbvie INC. | $525.01 | 2022-2025 | Xen Glaucoma Treatment System, Lumigan, Alphagan P |
| Sun Pharmaceutical Industries INC. | $402.57 | 2022-2025 | Cequa |
| New World Medical,INC. | $319.41 | 2021-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $214.07 | 2021 | |
| Rxsight INC | $198.18 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $189.31 | 2022-2025 | Miebo, Xiidra |
| Sight Sciences, INC. | $174.94 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Harrow Eye, LLC | $148.40 | 2024-2025 | Vevye |
| Coopervision INC. | $143.26 | 2024 | Misight Contact Lens |
| Astellas Pharma US INC | $100.00 | 2024 | Izervay |
| Thea Pharma INC. | $96.68 | 2023-2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $74.35 | 2023-2025 | Tyrvaya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $63.52 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $62.80 | 2023 | |
| Ani Pharmaceuticals, INC. | $27.43 | 2023 | Purified Cortrophin Gel |
| Allergan, INC. | $24.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhillon Zaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.